# Liminatus Pharma, Inc. Class A Common Stock (LIMN)

> Healthcare · US · Reports in USD

Fundamental indicators from Sponda, adjusted for inflation.

[HTML version](https://sponda.capital/en/LIMN/fundamentals)

## Annual figures

| Year | Revenue (M) | Net Inc. (M) | FCF (M) | Debt (M) | Equity (M) |
| --- | --- | --- | --- | --- | --- |
| 2026 | $ 0 | $ -1.12M | $ -2.02M | $ 1.44M | $ -132.6K |
| 2025 | $ 0 | $ -10.12M | $ -10.21M | $ 1.44M | $ -9.81M |
| 2024 | $ 0 | $ -3.99M | $ -952.20M | $ 5.12M | $ -15.87M |
| 2023 | $ 0 | $ -876.3K | $ -1.26M | $ 16.05M | $ -10.69M |

Columns not available in this view: annualPriceMultiples, dividends. They require live market data and are shown on the HTML page instead.

## Leverage and liquidity

| Indicator | Value |
| --- | --- |
| Gross Debt / Eq | -10.88 |
| Liabilities / Eq | -22.04 |
| Current Ratio | 0.96 |

## Other views

- [Metrics](https://sponda.capital/en/LIMN.md)
- [Charts](https://sponda.capital/en/LIMN/charts.md)
- [Compare](https://sponda.capital/en/LIMN/compare.md)
- [Indicator definitions](https://sponda.capital/en/screener.md)

Data as of 2026-08-27.